Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.41 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | PPARA | Q07869 | 5/20 | 0.40 |
| ▸ | PPARG | P37231 | 4/20 | 0.40 |
| ▸ | CTSS | P25774 | 4/20 | 0.39 |
| ▸ | CTSK | P43235 | 4/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31407782 | 0.89 | ITGB3 (0.45) | ITGB3ITGA2BNAMPTHDAC1ACE | |
| SCHEMBL5076532 | 0.87 | NAMPT (0.47) | ITGB3ITGA2BNAMPTHDAC1ACE | |
| SCHEMBL7260124 | 0.85 | NAMPT (0.44) | ITGB3ITGA2BNAMPTHDAC1GRIN2B | |
| SCHEMBL31407652 | 0.84 | KLK5 (0.48) | ITGB3ITGA2BNAMPTHDAC1ACE | |
| SCHEMBL2217180 | 0.83 | SLC7A5 (0.47) | ITGB3ITGA2BNAMPTHDAC1GRIN2B | |
| SCHEMBL2217184 | 0.83 | SLC7A5 (0.47) | ITGB3ITGA2BNAMPTHDAC1GRIN2B | |
| SCHEMBL7257280 | 0.82 | NAMPT (0.46) | NAMPTHDAC1GRIN2BPPARAPPARG | |
| SCHEMBL6059170 | 0.81 | NAMPT (0.43) | ITGB3ITGA2BNAMPTHDAC1GRIN2B | |
| SCHEMBL164105 | 0.80 | HDAC1 (0.52) | NAMPTHDAC1GRIN2B | |
| SCHEMBL29523504 | 0.80 | HDAC1 (0.52) | NAMPTHDAC1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309207-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2016-04-12 | — | — | US | disclosed |
| US-8722655-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of tafia | SANOFI (FR) | 2014-05-13 | — | — | US | disclosed |
| US-20110178130-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| US-20110082151-A1 | SULFONYLUREA MODULATORS OF ENDOTHELIN RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178130-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | TFPI, TFPI2, SERPINC1 | ITGB3 3218/4885ITGA2B 1249/4885NAMPT 1007/4885 |
| US-20110082151-A1 | SULFONYLUREA MODULATORS OF ENDOTHELIN RECEPTOR | EDNRA, EDNRB, GLP1R | ITGB3 4033/4885ITGA2B 4496/4885NAMPT 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.